Prostate cancer

There are 1,069 papers on prostate cancer in aging research: 77 trials and 552 observational studies in people, 35 in animals, 20 in cells, 303 reviews. The newest story, Nov 12, 2026: “Water chemicals linked to death risk in men with prostate cancer”.

Disease

1,069 papers study it358 more mention it302 findings

91 new papers in 30 daysSee all 1,427 papers on prostate cancer

“Prostate cancer cumulative incidence at 15 years was 7.08% (95% CI 6.95%-7.21%) in those invited to screening, compared with 6.94% (95% CI 6.82%-7.06%) in the control arm”
Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised TrialInternational journal of cancer2026doi:10.1002/ijc.70492
  • Human trial77
  • Humans552
  • Animals35
  • Cells20
  • In silico52

Interventions

19

Testosterone

no changein humans13HR 0.89–1.2

13 studies
  1. Testosterone showed no clear effect on prostate cancer in humans (HR 1.07, 95% CI 0.47-2.42).

    “The number of participants with any prostate cancer did not differ between the TRT (12 [0.46%]) and placebo (11 [0.42%]) groups (HR, 1.07; 95% CI, 0.47-2.42; P =.87).”

    Human trial21.8 (14.2) months in the TRT group and 21.6 (14.0) months in the placebo groupmalesn = 5,204

    Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial

    JAMA network open

  2. Testosterone showed no clear effect on prostate cancer in humans (hypogonadism and CVD or increased CVD risk).

    “the incidences of any prostate cancer, acute urinary retention, invasive surgical procedures, prostate biopsy, and new pharmacologic treatment also did not differ significantly.”

    Human trialhypogonadism and CVD or increased CVD risktopical 1.62% gelprostatemean 21.8 monthsmalesn = 5,204

    Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial

    JAMA network open

  3. Testosterone was not clearly linked with prostate cancer in chronic kidney disease stages 3-5 with hypogonadism.

    “No significant differences were observed for cardiovascular outcomes, prostate cancer or dementia.”

    Humansin chronic kidney disease stages 3-5 with hypogonadismmedian 3.7 yearsmales

    Safety of Testosterone Therapy in Chronic Kidney Disease: A Propensity Score-Matched Cohort Study

    The world journal of men's health

  4. Testosterone was not clearly linked with prostate cancer in humans (men with low testosterone levels and normal PSA) (HR 0.89; 95% CI 0.70-1.13).

    “testosterone treatment was not associated with incident aggressive CaP (HR 0.89; 95% CI 0.70-1.13)”

    Humansmen with low testosterone levels and normal PSAmalesn = 147,593

    Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels

    PloS one

  5. Testosterone was not clearly linked with prostate cancer in humans (long-term TT) (HR 1.2, 95% CI 0.54-2.50).

    “There was no difference in prostate cancer risk based on TT status (HR 1.2, 95% CI 0.54-2.50).”

    Humanslong-term TTmales

    Testosterone therapy and cancer risk

    BJU international

  6. Testosterone showed no clear effect on prostate cancer in humans (hypogonadal men).

    “TTh is likely not associated with increased risk of PCa incidence or recurrence.”

    Reviewhypogonadal menmales

    Controversies in Testosterone Therapy

    Sexual medicine reviews

  7. Testosterone showed no clear effect on prostate cancer in humans.

    “it does not appear to increase the risk of prostate cancer”

    Reviewmales

    Benefits and risks of testosterone therapy in older men

    Minerva urologica e nefrologica = The Italian journal of urology and nephrology

  8. Testosterone showed no clear effect on prostate cancer in humans.

    “There remains no evidence that TRT is associated with increased risk of prostate cancer”

    Reviewmales

    Testosterone Replacement Therapy and Mortality in Older Men

    Drug safety

  9. Testosterone showed no clear effect on prostate cancer in humans.

    “There remains no evidence that TRT is associated with increased risk of prostate cancer”

    Review

    An update on the role of testosterone replacement therapy in the management of hypogonadism

    Therapeutic advances in urology

  10. Testosterone showed no clear effect on prostate cancer in humans (age-related male hypogonadism).

    “Only 3 studies provided data with respect to the development of prostate cancer, and rates were similar between those that received treatment and controls.”

    Reviewage-related male hypogonadism3 to 12 monthsmales

    The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis

    Medicine

All 14

More on Testosterone

Testosterone replacement therapy

no changein humans4

4 studies
  1. Testosterone replacement therapy was not clearly linked with prostate cancer in humans.

    “TRT users did not exhibit a higher incidence or mortality rate of PCa compared to non-users.”

    Humans18 yearsmalesn = 78,615

    Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men

    Acta oncologica (Stockholm, Sweden)

  2. Testosterone replacement therapy showed no clear effect on prostate cancer in humans (older men with low testosterone levels).

    “The risk ratios of adverse events, including elevated prostate-specific antigen, acute coronary syndrome, and prostate cancer, were not significantly different.”

    Reviewolder men with low testosterone levelsmalesn = 2,043

    Effects of Testosterone Replacement Therapy on Muscle Strength in Older Men with Low to Low-Normal Testosterone Levels: A Systematic Review and Meta-Analysis

    Gerontology

  3. Testosterone replacement therapy showed no clear effect on prostate cancer in patients without known CaP.

    “in patients without known CaP, the evidence seems sufficient to think that androgen therapy does not increase the risk of subsequent discovery of CaP.”

    Reviewin patients without known CaP

    Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer

    Urologic oncology

  4. Testosterone replacement therapy showed no clear effect on prostate cancer in humans (short-term or long-term TRT vs placebo) (ORs across routes and durations non-significant (all P>0.10)).

    “TRT is the short-term safety and does not promote prostate cancer development or progression”

    Reviewshort-term or long-term TRT vs placebo<12 months to 12-36 monthsmalesn = 2,351

    The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis

    Prostate cancer and prostatic diseases

More on Testosterone replacement therapy

Mediterranean diet

no changein humans1RR 0.98

1 study
  1. Mediterranean diet showed no clear effect on prostate cancer in humans (high versus low Mediterranean diet adherence) (RR 0.98, 95% CI 0.93–1.04).

    “we did not find a statistically significant difference in risk of prostate cancer in men with high versus low Mediterranean diet adherence”

    Reviewhigh versus low Mediterranean diet adherencemales

    Mediterranean diet and risk of prostate cancer: a systematic review and meta-analysis of observational studies

    BMC nutrition

More on Mediterranean diet

Green tea

no changein humans1RR 0.52

1 study
  1. Green tea showed no clear effect on prostate cancer in humans (RR = 0.52; 95% CI: 0.22-1.23).

    “prostate cancer incidence (RR = 0.52; 95% CI: 0.22-1.23)”

    Review

    Effects of Green Tea Supplementation on Chemoprevention at Different Stages of Carcinogenesis: A Systematic Review

    Phytotherapy research : PTR

More on Green tea

Population-based screening

no changein silico1

1 study
  1. Population-based screening showed no clear effect on prostate cancer in silico (early-stage prostate cancer) (similar).

    “The overall incidence of early-stage prostate cancer was similar.”

    In silicoearly-stage prostate cancer

    Effect of Implementing Population-Based Prostate-Specific Antigen Screening on Testing Rates and Prostate Cancer Overdiagnosis in England: A Statistical Modelling Study

    International journal of cancer

More on Population-based screening

Risk-adapted prostate-specific antigen screening guidelines

upin humans1

1 study
  1. Risk-adapted prostate-specific antigen screening guidelines increase prostate cancer in humans (primary care encounters) (2.7-fold (0.25 to 0.68 per 100, p = .007)).

    “Total PCa incidence rose 2.7-fold (0.25 to 0.68 per 100, p = .007), with incidence of cancer beyond grade group 1 increasing 3-fold (p = .008).”

    Human trialprimary care encounters15-monthmalesn = 4,252

    A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population

    Cancer

More on Risk-adapted prostate-specific antigen screening guidelines

Cruciferous vegetables

downin humans1

1 study
  1. Cruciferous vegetables protect against prostate cancer in humans.

    “Cruciferous vegetables show a strong protective factor, supported by epidemiologic data”

    Review

    The role of nutrition in prostate cancer risk, progression, and mortality: A comprehensive review

    Clinical nutrition ESPEN

More on Cruciferous vegetables

Menadione sodium bisulfite

downin mice1

1 study
  1. Menadione sodium bisulfite inhibits prostate cancer in mice.

    “menadione sodium bisulfite (MSB)] suppresses PC progression in mice”

    Animalsin mice

    Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function

    Science (New York, N.Y.)

More on Menadione sodium bisulfite

Glucosamine

no changein humans1HR 1.03

1 study
  1. Glucosamine was not clearly linked with prostate cancer in patients with osteoarthritis (HR 1.03, 95% CI 0.88–1.22).

    “1.03 (95% CI 0.88-1.22) for prostate cancer”

    Humansin patients with osteoarthritis

    Glucosamine and Cancer Incidence in Osteoarthritis: A Prevalent New-User Cohort Design

    Arthritis care & research

More on Glucosamine

Multivitamins

no changein humans1HR 0.98

1 study
  1. Multivitamins were not clearly linked with prostate cancer in humans (men with nonmetastatic prostate cancer) (HR 0.98, 95% CI 0.74-1.30).

    “post-diagnostic multivitamin use was not associated with risk of lethal prostate cancer (HR [95% CI], 0.98 [0.74-1.30])”

    Humansmen with nonmetastatic prostate cancermedian follow-up of 11 yearsmalesn = 4,756

    Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer

    British journal of cancer

More on Multivitamins

All 19

Effects

10

Prostate-specific antigen

upin humans1

1 study
  1. Prostate cancer is linked with higher prostate-specific antigen in humans (symptomatic referred patients).

    “Patients with csPCa had consistently higher PSA levels.”

    Humanssymptomatic referred patientsmales

    The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density

    BJU international

More on Prostate-specific antigen

Activities of daily living

no changein humans1

1 study
  1. Prostate cancer was not clearly linked with activities of daily living in humans (2 to 7 years post-curative treatment) (95.6% vs. 96.3% ADL, 82.7% vs. 81.9% IADL).

    “Older prostate cancer survivors reported similar health, independence in ADL and use of emergency room and hospital admissions as matched controls.”

    Humans2 to 7 years post-curative treatmentmales

    Self-reported health, function, and use of health care services in older prostate cancer survivors compared to matched controls: a cross-sectional study

    Journal of cancer survivorship : research and practice

General health

no changein humans1

1 study
  1. Prostate cancer was not clearly linked with general health in humans (2 to 7 years post-curative treatment) (58.7% vs. 62.7% good, 11.2% vs. 6.8% very good).

    “Regression models showed no significant differences between survivors and controls.”

    Humans2 to 7 years post-curative treatmentmales

    Self-reported health, function, and use of health care services in older prostate cancer survivors compared to matched controls: a cross-sectional study

    Journal of cancer survivorship : research and practice

Cognitive impairment

no changein humans1

1 study
  1. Prostate cancer was not clearly linked with cognitive impairment in humans With or without androgen deprivation therapy, relative to non-prostate cancer controls (Overall prevalence 4%-13%; no between-group difference).

    “The overall prevalence of cognitive impairment was low (4%-13%) and did not differ between the groups.”

    HumansWith or without androgen deprivation therapy, relative to non-prostate cancer controlsmales

    Does androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study

    BMJ open

More on Cognitive impairment

Carboplatin sensitivity

upin humans1

1 study
  1. Prostate cancer is linked with higher carboplatin sensitivity in humans.

    “prostate cancer-specific DNA repair phenotypes characterized by increased PARP activities and carboplatin-sensitivities”

    Humanslymphocytemales

    Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer

    Mechanisms of ageing and development

DNA repair

no changein humans1

1 study
  1. Prostate cancer was not clearly linked with DNA repair in humans (error-prone double-strand break repair).

    “error-prone DNA double-strand break repair was not activated in prostate cancer patients”

    Humanserror-prone double-strand break repairlymphocytemales

    Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer

    Mechanisms of ageing and development

More on DNA repair

Decline in muscular strength and physical function

no changein humans1

1 study
  1. Prostate cancer was not clearly linked with decline in muscular strength and physical function in humans (compared with matched non-cancer controls, from diagnosis onwards).

    “All men experienced similar declines in strength and physical function over an equivalent amount of time.”

    Humanscompared with matched non-cancer controls, from diagnosis onwardsapproximately 7 yearsmales

    Trajectories in muscular strength and physical function among men with and without prostate cancer in the health aging and body composition study

    PloS one

Histopathological changes in peri-prostatic ganglion cells

upin humans1

1 study
  1. Prostate cancer is linked with higher histopathological changes in peri-prostatic ganglion cells in humans.

    “All the changes were more marked in the peri-prostatic ganglion cells of patients with prostatic adenocarcinoma compared with those with benign prostate hyperplasia”

    Humansperi-prostatic sympathetic gangliamalesn = 36

    Morphological changes in peri-prostatic sympathetic ganglion cells in aging males

    Molecular and clinical oncology

Mortality

no changein humans1HR 1.14

1 study
  1. Prostate cancer was not clearly linked with mortality in humans (Compared with age-matched controls; models using VES-13 vulnerability thresholds) (VES-13≥3: HR=1.14, p=0.59; VES13≥6: HR=1.06, p=0.83).

    “Men with a PCa diagnosis were not more likely to die compared to age-matched controls”

    HumansCompared with age-matched controls; models using VES-13 vulnerability thresholdsmales

    Which better predicts mortality among older men, a prostate cancer (PCa) diagnosis or vulnerability on the Vulnerable Elders Survey (VES-13)? A retrospective cohort study

    Journal of geriatric oncology

Free choline

no changein humans1

1 study
  1. Prostate cancer was not clearly linked with free choline in humans (Compared with men with benign prostatic hyperplasia) (Median 10.0 versus 9.7 μmol/L).

    “The presence of PCa was not associated with significant changes in plasma concentrations of choline or methyl metabolites.”

    HumansCompared with men with benign prostatic hyperplasiaplasmamales

    Choline-phospholipids inter-conversion is altered in elderly patients with prostate cancer

    Biochimie

More on Free choline

Upstream

10

HPV serology

no changein humans1

1 study
  1. HPV serology showed no clear effect on prostate cancer in humans (Serology-based assessment; very low evidence certainty).

    “whereas HPV serology showed no clear association.”

    ReviewSerology-based assessment; very low evidence certainty

    Sexual behavior-related exposures, sexually transmitted infections, and viral markers in relation to prostate cancer risk: a systematic review and meta-analysis

    Frontiers in oncology

More on HPV serology

Sex hormones

no changein humans1

1 study
  1. Sex hormones were not clearly linked with prostate cancer in men with T2DM.

    “sex hormone levels showed no significant association in men with T2DM.”

    Humansin men with T2DMmales

    Polygenic Risk Score Predicts Prostate Cancer Risk Independent of Type 2 Diabetes

    Diabetes, obesity & metabolism

More on Sex hormones

Handgrip strength

no changein humans1

1 study
  1. Handgrip strength was not clearly linked with prostate cancer in humans.

    “Low HGS does not independently predict prostate cancer risk in older European men.”

    Humansmales

    Evaluation of handgrip strength and prostate cancer risk using propensity score matching in 64,371 European men

    Maturitas

More on Handgrip strength

Body mass index

no changein humans1

1 study
  1. Body mass index showed no clear effect on prostate cancer in systematic review of 24 studies.

    “Thus, the overall evidence supports a neutral relationship between BMI and prostate cancer risk.”

    Reviewin systematic review of 24 studies

    Body mass index and prostate cancer incidence: a comprehensive systematic review

    Frontiers in oncology

More on Body mass index

Diabetes mellitus

no changein humans1

1 study
  1. Diabetes mellitus was not clearly linked with prostate cancer in humans (compared to those without diabetes) (aHR 0.94, 95% CI 0.72-1.21).

    “or prostate cancer (aHR: 0.94, 95% CI = 0.72-1.21) when compared to those without diabetes.”

    Humanscompared to those without diabetesmalesn = 192,456

    Associations of Diabetes, Smoking, and Metabolic Factors With the Risk of Breast and Prostate Cancers: A Population-Based Retrospective Cohort Study

    Cancer medicine

More on Diabetes mellitus

Testosterone

no changein humans1

1 study
  1. Testosterone was not clearly linked with prostate cancer in humans.

    “Baseline testosterone was not associated with risk of incident non-fatal and fatal cancer, nor incident prostate cancer.”

    Humansmalesn = 12,280

    SAT-156 Associations of Testosterone, Dihydrotestosterone and Sex Hormone-binding Globulin with Risks of Cancer Death, Incident Cancer, and Incident Prostate Cancer in Men. Individual Participant Data Meta-analyses

    ENDO 2025 abstract

More on Testosterone

JUN

downin mice1

1 study
  1. JUN inhibits prostate cancer in mice (shown by Jun depletion in Pten-deficient mice).

    “As a result, JUN depletion in Pten-deficient prostates interfered with the senescence-associated immune clearance and accelerated tumor growth.”

    Animalsshown by Jun depletion in Pten-deficient miceprostate

    JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression

    Molecular cancer

More on JUN

IL-6

no changein humans1

1 study
  1. IL-6 was not clearly linked with prostate cancer in humans.

    “There was no significant association between any of the other cytokines measured and PCa risk.”

    Humansserumaverage 6 years of follow-upmalesn = 798

    Circulating IL-10 is associated with reduced risk of prostate cancer in a prospective cohort of elderly men: the MrOS Study

    Cancer causes & control : CCC

More on IL-6

NETO2

upin mice1

1 study
  1. NETO2 increases prostate cancer in mice.

    “NETO2 drove PCa cell proliferation, migration and invasion in vitro, and promoted growth of PCa cells in vivo.”

    Animals

    NETO2 promotes progression of prostate cancer by inhibiting the cellular senescence pathway

    Research SquarePreprint

More on NETO2

Carboxymethyllysine

no changein humans1

1 study
  1. Carboxymethyllysine was not clearly linked with prostate cancer in humans.

    “CML was not associated with the risk of prostate cancer”

    Humans12 yearsmalesn = 3,149

    Neither Hormonal Factors Nor AGEs Explain Lower Prostate Cancer Risk in Older Men With Diabetes Mellitus

    The Journal of clinical endocrinology and metabolism

More on Carboxymethyllysine

Associations

192

Telomere length

upin humans6upin silico2HR 1.444

7 studies
  1. Telomere length is linked with a higher risk of prostate cancer in humans (HR = 1.444, 95% CI 1.247–1.673, P < 0.001).

    “longer LTL was substantially associated with higher risk of PCa, with associations remaining robust after adjusting for potential covariates (hazard ratio (HR) = 1.444; 95% confidence interval (CI) = 1.247, 1.673, P < 0.001).”

    Humansmales

    Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: results from a large-scale longitudinal cohort study

    Journal of global health

  2. Telomere length is linked with a higher risk of prostate cancer in humans (OR 1.4200, 95% CI 1.1489-1.7550).

    “and prostate cancer (OR = 1.4200, 95% CI 1.1489-1.7550, P = 0.0012).”

    Humans

    Causal effect between telomere length and thirteen types of cancer in Asian population: a bidirectional Mendelian randomization study

    Aging clinical and experimental research

  3. Telomere length is linked with a higher risk of prostate cancer in humans (+34% per 1-s.d extension).

    “Every 1-s.d extension of LTL increased the risk of PCs by 34%.”

    Humansmales

    Mendelian randomization evidence based on European ancestry for the causal effects of leukocyte telomere length on prostate cancer

    Human genomics

  4. Telomere length is associated with prostate cancer in humans (1.155-fold to 1.349-fold, all p < .001).

    “individuals in the longer quartiles of LTL were observed to have a higher risk of PCa (1.155-fold to 1.349-fold, all p < .001)”

    Humans

    Leukocyte Telomere Length and the Risk of Prostate Cancer and Benign Prostatic Hyperplasia: Insights From UK Biobank and Mendelian Randomization Study

    The journals of gerontology. Series A, Biological sciences and medical sciences

  5. Telomere length is linked with a higher risk of prostate cancer in humans (OR 1.406, 95% CI 1.327 to 1.489, P < 0.001).

    “the genetically determined per 1-standard deviation rise in LTL correlated significantly with an average 40.6% increase in the PCa risk, with an average odds ratio of 1.406”

    Humans

    Mendelian randomization study on the causal relationship between leukocyte telomere length and prostate cancer

    PloS one

  6. Telomere length is linked with a higher risk of prostate cancer in White men, highest vs lowest quartile (OR = 1.90; 95% CI = 1.08-3.36).

    “those with telomere length in the highest quartile had 1.9-fold greater adjusted risk of prostate cancer compared with men with prostate telomere lengths in the lowest quartile [OR = 1.90; 95% confidence interval (CI) = 1.08-3.36].”

    Humansin White men, highest vs lowest quartilemales

    Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

  7. Telomere length raises the risk of prostate cancer in silico.

    “Mendelian randomization analysis indicated a positive causal relationship between LTL and PCa.”

    In silico

    Investigating the Shared Genetic Architecture Between Leukocyte Telomere Length and Prostate Cancer

    The world journal of men's health

  8. Telomere length is associated with prostate cancer in silico (genetic correlation=0.066, p=0.017).

    “Our study demonstrated a global genetic correlation between LTL and PCa (genetic correlation=0.066, p=0.017)”

    In silico

    Investigating the Shared Genetic Architecture Between Leukocyte Telomere Length and Prostate Cancer

    The world journal of men's health

  9. Telomere length raises the risk of prostate cancer in silico (OR 1.427, 95% CI 1.197-1.702, p < .001).

    “genetically predicted longer LTL resulted in a 1.427-fold risk of PCa (odds ratio [OR] = 1.427, 95% confidence interval [CI] = 1.197-1.702, p < .001)”

    In silico

    Leukocyte Telomere Length and the Risk of Prostate Cancer and Benign Prostatic Hyperplasia: Insights From UK Biobank and Mendelian Randomization Study

    The journals of gerontology. Series A, Biological sciences and medical sciences

More on Telomere length

Polygenic risk score

upin humans6OR 1.61–2.19

6 studies
  1. Polygenic risk score is associated with prostate cancer in UK Biobank (p<0.001).

    “Five genes (ATM, BRCA2, CHEK2, HOXB13, MSH2) and the PRS were independently associated with PCa risk (all p<0.001) in UKB.”

    Humansin UK Biobankmalesn = 218,484

    Combined genetic score better distinguishes prostate cancer risk

    Journal of medical genetics

  2. Polygenic risk score is associated with prostate cancer in humans (OR 1.92 (95% CI, 1.72 to 2.13)).

    “A one-unit PRS change was associated with an OR of 1.92 (95% CI, 1.72 to 2.13).”

    Humansmales

    Association of Family History and Polygenic Risk Scores With Prostate Cancer in Africa

    JCO global oncology

  3. Polygenic risk score is linked with a higher risk of prostate cancer in humans (multi-ancestry cohort) (OR 1.61 to 2.19).

    “In ancestry-stratified testing, the PRS showed strong associations with prostate cancer risk, with odds ratios (ORs) per standard deviation (SD) increase ranging from 1.61”

    Humansmulti-ancestry cohort

    Validation and context-dependent effects of a prostate cancer polygenic risk score in the All of Us Research Program

    American journal of human genetics

  4. Polygenic risk score predicts prostate cancer in humans (HR 6.527).

    “Genetic predisposition, assessed by PRS, was a strong independent predictor of prostate cancer (HR for high vs low PRS: 6.527).”

    Humansmalesn = 224,272

    Air Pollution, Lifestyle, and Genetic Risk: A Multidimensional Study of PM2.5 Constituents and Prostate Cancer

    The Journal of urology

  5. Polygenic risk score is associated with prostate cancer in humans (OR 1.80 per SD (95% CI 1.65-1.96)).

    “The PRS was also associated with prevalent prostate cancer (odds ratio = 1.80 per SD (95% CI 1.65-1.96), p < 0.001).”

    Humansmales

    A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease

    Cancers

  6. Polygenic risk score predicts prostate cancer in humans (HR 1.52 per SD (95% CI 1.33-1.74)).

    “The PRS predicted incident risk with a hazard ratio (HR) of 1.52 per standard deviation (SD) (95% confidence interval (CI) 1.33-1.74, p < 0.001).”

    Humansmedian 4.6 yearsmalesn = 5,701

    A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease

    Cancers

  7. Polygenic risk score predicts prostate cancer in humans (Asian men in the highest polygenic risk score decile) (4- to 5-fold increased risk in the highest decile).

    “population-specific PRS models effectively stratify prostate cancer risk in Asian men, with individuals in the highest decile showing a 4- to 5-fold increased risk.”

    ReviewAsian men in the highest polygenic risk score decilemales

    Polygenic risk and germline genetics for prostate cancer in Asians: Where do we stand?

    Investigative and clinical urology

More on Polygenic risk score

Prostate-specific antigen

upin humans6HR 2.01

6 studies
  1. Prostate-specific antigen is associated with prostate cancer in humans (increasing PSA levels) (91% vs. 38% at PSA levels ≥ 20 μg/L).

    “increasing with higher PSA levels (91% vs. 38% at PSA levels ≥ 20 μg/L).”

    Humansincreasing PSA levelsprostate1 yearmalesn = 10,777

    Detection of prostate cancer by magnetic resonance imaging before biopsy - real-world evidence from a nationwide cohort study

    Scandinavian journal of urology

  2. Prostate-specific antigen is linked with a higher risk of prostate cancer in humans (doubling of total PSA in joint model) (HR 2.01, 95% CI 1.99-2.02).

    “doubling of the total PSA values was associated with a hazard ratio (HR) of 2.01 (95% CI: 1.99-2.02; P < .001) for diagnosis”

    Humansdoubling of total PSA in joint modelmales

    Joint modelling of PSA dynamics and prostate cancer risks: A population-based study

    medRxivPreprint

  3. Prostate-specific antigen predicts prostate cancer in humans (asymptomatic men undergoing PSA testing) (observed-to-expected ratio > 1).

    “The observed-to-expected ratio was greater than 1 for initial PSA values >=3 ng/mL and increased progressively with higher PSA levels.”

    Humansasymptomatic men undergoing PSA testingmalesn = 414,731

    The prostate biopsy during the follow-up of a cohort of 400,000 asymptomatic men undergoing PSA testing in the Agency for Health Protection of the Metropolitan Area of Milan

    Epidemiologia e prevenzione

  4. Prostate-specific antigen predicts prostate cancer in humans (4.780 ng/mL).

    “The optimal prostate-specific antigen cutoff values for patients aged 50-59 years, 60-69 years, 70-79 years, and over 80 years were 3.900 ng/mL, 4.014 ng/mL, 4.080 ng/mL, and 4.780 ng/mL, respectively.”

    Humansmales

    Screening for prostate cancer in a city in Japan: age-specific prostate-specific antigen cutoff thresholds

    Cancer causes & control : CCC

  5. Prostate-specific antigen predicts prostate cancer in fragile men with a life expectancy of over 15 years.

    “Prostate-specific antigen (PSA) testing can be used to identify prostate cancer in its early and treatable stages in fragile men with a life expectancy of over 15 years.”

    Reviewin fragile men with a life expectancy of over 15 yearsmales

    Prostate- Specific Antigen (PSA) Significance in Frail and Sarcopenic Men

    Preprints.orgPreprint

  6. Prostate-specific antigen predicts prostate cancer in humans (frail men with more than 15 years life expectancy).

    “PSA in frail men with more than 15 years life expectancy can detect prostate cancer in curable stages”

    Reviewfrail men with more than 15 years life expectancymales

    Prostate- Specific Antigen (PSA) Significance in Frail Men

    Preprints.orgPreprint

More on Prostate-specific antigen

Testosterone

downin humans3upin humans2no changein humans1RR 0.62–0.648

6 studies
  1. Testosterone is associated with prostate cancer in humans (hypogonadism; testosterone replacement therapy versus no therapy) (1.9% vs 2.9%; RR 0.648).

    “Using TRT is associated with moderately lower rates of mortality, atrial fibrillation, stroke, and prostate cancer in hypogonadal men versus no TRT.”

    Humanshypogonadism; testosterone replacement therapy versus no therapy3 yearsmalesn = 133,584

    Benefits of Testosterone Replacement Therapy in Hypogonadal Males

    Journal of the American Board of Family Medicine : JABFM

  2. Testosterone is associated with prostate cancer in humans (symptomatic androgen deficiency) (14 new cases, one case per 212 years).

    “The incidence of PCa during long-term TRT was equivalent to that expected in the general population.”

    Humanssymptomatic androgen deficiencyup to 20 yearsmales

    Is testosterone treatment good for the prostate? Study of safety during long-term treatment

    The journal of sexual medicine

  3. Testosterone lowers the risk of prostate cancer in humans.

    “multiple studies showing that TTh is associated with reduced PCa risk.”

    Reviewmales

    Recognizing the True Value of Testosterone Therapy in Health Care

    Androgens: clinical research and therapeutics

  4. Testosterone lowers the risk of prostate cancer in humans (hypogonadism or low testosterone level) (RR=0.62, 95%CI [0.39,0.99]).

    “TT administration led to fewer Pca patients (RR=0.62, 95%CI [0.39,0.99], I2=0%)”

    Reviewhypogonadism or low testosterone level

    The effect of different administrations of testosterone therapy on adverse prostate events: A Bayesian network meta-analysis

    Frontiers in endocrinology

  5. Testosterone raises the risk of prostate cancer in humans.

    “their long-term use may be associated with severe adverse effects (i.e. increased risk of prostate cancer, stroke and myocardial infarction”

    Reviewlong-term

    'Forever Young'-Testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises

    Human reproduction (Oxford, England)

  6. Testosterone raises the risk of prostate cancer in humans.

    “evidence suggests that prostate cancer could, in fact, be stimulated by TST”

    Review

    Testosterone therapy and prostate cancer--safety concerns are well founded

    Nature reviews. Urology

More on Testosterone

Age

upin humans3upin reviews1OR 1.11

4 studies
  1. age is linked with a higher risk of prostate cancer in humans across all SDI regions.

    “Meanwhile, APC analysis showed that incidence increased with age in all SDI regions.”

    Humansacross all SDI regionsmales

    Global Trends in Prostate Cancer Incidence Among Men Aged 55+ (1992-2021): An Age-Period-Cohort Analysis

    The Prostate

  2. Age predicts prostate cancer in patients undergoing HoLEP (OR 1.11, 95% CI 1.03-1.19, p=0.005).

    “older age (OR 1.11, 95% CI 1.03-1.19, p=0.005), higher total PSA (OR 1.13, 95% CI 1.04-1.22, p= 0.03), and higher PSA density”

    Humansin patients undergoing HoLEP

    Rates of incidental prostate cancer following HoLEP Can it be predicted preoperatively?

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada

  3. Age is linked with a higher risk of prostate cancer in risk signatures (hazard ratio 1.15 per year, 95% confidence interval 1.13-1.18).

    “Risk signatures confirmed age as the dominant risk factor (hazard ratio 1.15 per year, 95% confidence interval 1.13-1.18)”

    Humansin risk signatures

    Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort

    ESMO real world data and digital oncology

  4. Age raises the risk of prostate cancer.

    “Ageing is also the strongest demographic risk factor for prostate cancer”

    Review

    Age-related changes in prostate structure and function: A comprehensive review

    International Journal of Homoeopathic Sciences

BRCA2

upin humans3

3 studies
  1. BRCA2 is linked with a higher risk of prostate cancer in humans (BRCA2 pathogenic variant carriers) (SIR = 3.6, 95% CI 1.9-6.8).

    “For BRCA2 PV carriers, increased risks of pancreatic (SIR = 6.6, 95% CI 3.8-11.6), prostate (SIR = 3.6, 95% CI 1.9-6.8) and stomach (SIR = 3.1, 95% CI 1.01-9.8) cancer were observed”

    HumansBRCA2 pathogenic variant carriers

    Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: a prospective cohort study

    BMC medicine

  2. BRCA2 raises the risk of prostate cancer in humans.

    “Germline BRCA2 mutation carriers represent the most clearly defined high-risk group, with evidence of earlier onset, higher incidence, and a greater proportion of aggressive disease”

    Review

    High-risk prostate cancer screening – More Bang for our buck?

    Journal of Clinical Urology

  3. BRCA2 raises the risk of prostate cancer in humans (early and aggressive disease).

    “BRCA2 mutations have been added as risk factors for early and aggressive disease.”

    Reviewearly and aggressive diseasemales

    EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    European urology

More on BRCA2

Diabetes mellitus

downin humans2upin humans1HR 0.78–1.18

3 studies
  1. Diabetes mellitus is linked with a higher risk of prostate cancer in humans (HR: 1.18, 95% CI: 1.08~1.29).

    “Participants with baseline diabetes exhibited an 18% elevated risk of developing PCa compared with CMD-free counterparts (HR: 1.18, 95% CI: 1.08~1.29).”

    Humans17-year mean follow-up

    Cardiometabolic comorbidities and prostate cancer risk: evidence from the prostate, lung, colorectal, and ovarian cancer screening trial

    Frontiers in oncology

  2. Diabetes mellitus is linked with a lower risk of prostate cancer in humans (HR = 0.78, 95% CI = 0.68–0.90, p < 0.01).

    “matched cohort analyses confirmed a protective association with diabetes mellitus (HR = 0.78, 95% CI = 0.68–0.90, p < 0.01).”

    Humans14.1 yearsmales

    Elevated low-density lipoprotein cholesterol levels and prostate cancer risk: UK Biobank evidence

    World journal of urology

  3. Diabetes mellitus is linked with a lower risk of prostate cancer in diabetes patients.

    “The results showed that risk of prostate cancer decreased in diabetes patients.”

    Humansin diabetes patients

    The association between diabetes mellitus and prostate cancer: a meta-analysis and Mendelian randomization

    Aging

More on Diabetes mellitus

IGF-1

upin humans3OR 1.1–1.51

3 studies
  1. IGF-1 is associated with prostate cancer in humans.

    “IGF-1 levels were positively associated with PrCa risk among both diabetic and non-diabetic men”

    Humansmales

    Polygenic Risk Score Predicts Prostate Cancer Risk Independent of Type 2 Diabetes

    Diabetes, obesity & metabolism

  2. IGF-1 is associated with prostate cancer in humans (Per 100 ng/mL increment in serum IGF-1) (OR 1.51, 95% CI 1.0–2.26 per 100 ng/mL increment).

    “positive association between serum levels of IGF-1 levels and risk of prostate cancer (OR = 1.51; 95% CI = 1.0-2.26 per 100 ng/mL increment)”

    HumansPer 100 ng/mL increment in serum IGF-1serummales

    Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study

    Journal of the National Cancer Institute

  3. IGF-1 is associated with prostate cancer in humans (OR = 1.10, 95% CI: 1.02-1.18, P = 0.0136).

    “higher serum IGF-I levels were associated with an increased risk of prostate cancer (OR = 1.10, 95% CI: 1.02-1.18, P = 0.0136)”

    Review

    Serum insulin-like growth factor-1 and epidemiological evidence of the risk of prostate cancer

    Frontiers in oncology

More on IGF-1

PSA density

upin humans3OR 1.095–3.02

3 studies
  1. PSA density is associated with prostate cancer in humans after propensity score matching in BPH patients undergoing HoLEP (OR 1.095, 95% CI 1.04-1.16, p=0.01).

    “elevated preoperative prostate-specfic antigen (PSA) density was significantly associated with the presence of iPCa (odds ratio [OR] 1.095, 95% confidence interval [CI] 1.04-1.16, p=0.01).”

    Humansafter propensity score matching in BPH patients undergoing HoLEP

    Rates of incidental prostate cancer following HoLEP Can it be predicted preoperatively?

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada

  2. PSA density predicts prostate cancer in humans (men with PSA levels of 4-10 ng/mL) (aOR = 1.81; 95% CI: 1.20-3.18; p = 0.013).

    “PSA density (aOR = 1.81; 95% CI: 1.20-3.18; p = 0.013) were independent predictors of csPCa”

    Humansmen with PSA levels of 4-10 ng/mLn = 286

    Urinary Epithelial Cell Adhesion Molecule (EpCAM) as a Noninvasive Biomarker for Detecting Clinically Significant Prostate Cancer in Men With Equivocal PSA Levels

    BioMed research international

  3. PSA density raises the risk of prostate cancer in humans (OR: 3.02; 95% CI: 1.50-6.07; p = 0.01).

    “PSA density >0.15 ng/mL/cc (OR: 3.02; 95% CI: 1.50-6.07; p = 0.01)”

    Review

    Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis

    Prostate cancer and prostatic diseases

More on PSA density

Dementia

downin humans3OR 0.96

3 studies
  1. Prostate cancer is linked with a lower risk of dementia in people with HIV (2yr RD: -1.9%; 95%CI: -2.3, -1.6).

    “lower among beneficiaries ≤50 with prostate cancer (2yr RD: -1.9%; 95%CI: -2.3, -1.6)”

    Humansin people with HIV2 years

    Incidence of dementia after a recent cancer diagnosis among people with HIV

    medRxiv : the preprint server for health sciencesPreprint

  2. Dementia is associated with prostate cancer in humans (Suggestive causal association in Mendelian randomization) (OR 0.960).

    “Dementia was suggestively causally associated with a reduced risk of PCa (odds ratio = 0.960, P = .014).”

    HumansSuggestive causal association in Mendelian randomization

    Insights into the impact of neuropsychiatric disorders on prostate diseases: A 2-sample Mendelian randomization study

    Medicine

  3. Prostate cancer is associated with dementia in humans (HR 0.69, 95% CI 0.49–0.97).

    “non-melanoma skin cancer and prostate cancer were associated with a reduced risk of dementia (0.79 [0.62-0.99]; 0.69 [0.49-0.97])”

    HumansMedian follow-up of 9.18 years

    Investigating the association between cancer and dementia risk: a longitudinal cohort study

    Alzheimer's research & therapy

More on Dementia

Prostate-specific antigen screening

upin humans2

2 studies
  1. Prostate-specific antigen screening raises the risk of prostate cancer in humans (CAP randomised trial of a one-off screen) (difference 0.14% (95% CI -0.04% to 0.37%)).

    “Prostate cancer cumulative incidence at 15 years was 7.08% (95% CI 6.95%-7.21%) in those invited to screening, compared with 6.94% (95% CI 6.82%-7.06%) in the control arm”

    Human trialCAP randomised trial of a one-off screen15 yearsmalesn = 189,386

    Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial

    International journal of cancer

  2. Prostate-specific antigen screening is associated with prostate cancer in humans (community-linkage PSA screening) (detection rate 0.99%).

    “Ultimately, 417 residents underwent prostate biopsy, with 171 being diagnosed with PCa, yielding a positive biopsy rate of 41.00% and a PCa detection rate of 0.99%.”

    Humanscommunity-linkage PSA screeningmalesn = 17,198

    Analysis of prostate cancer screening results and exploration of screening model for elderly males in Songjiang Rural Areas of Shanghai City based on PSA preliminary screening under the community linkage mode

    Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

More on Prostate-specific antigen screening

Black race

upin humans1OR 1.56

1 study
  1. black race raises the risk of prostate cancer in humans among patients who underwent 2-year biopsy (OR 1.56, 95% CI 0.98-2.46).

    “had higher PC risk, which approached, but did not reach significance (OR 1.56, 95%CI: 0.98-2.46).”

    Human trialamong patients who underwent 2-year biopsy2 yearsmales

    Black Race Predicts Poor Compliance and Higher Prostate Cancer Risk in a Multinational Repeat Biopsy Cohort: Secondary Analysis From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Clinical Trial

    The Prostate

PROSTest

upin humans1

1 study
  1. PROSTest predicts prostate cancer in humans (men evaluated for prostate cancer) (overall accuracy 91% (95% CI: 84.1-95.6%), NPV 89% (51.6-98.4%)).

    “PROSTest demonstrated an overall accuracy of 91% (95% CI: 84.1-95.6%) with an NPV of 89%.”

    Human trialmen evaluated for prostate cancerwhole bloodmalesn = 111

    Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate Cancer

    Cancers

More on PROSTest

TKTL1/Apo10 blood test

upin humans1

1 study
  1. TKTL1/Apo10 blood test predicts prostate cancer in humans (asymptomatic individual).

    “The combination of the TKTL1/Apo10 blood test and subsequent imaging made it possible to detect a developing prostate carcinoma in a localized stage.”

    Human trialasymptomatic individualmalesn = 1

    Detection of Prostate Carcinoma in an Asymptomatic Individual Initiated by an Immunological Biopsy-A Case Report

    Oncology research

More on TKTL1/Apo10 blood test

All 192

Trial sponsors

Funding

152 grants since 2016

National Cancer Institute$140MProstate Cancer FoundationUS Department of Veterans Affairs

Latest

Dec 2025: 27Jan 2026: 73Feb 2026: 53Mar 2026: 70Apr 2026: 26May 2026: 13Jun 2026: 15Jul 2026: 24Aug 2026: 50Sep 2026: 53Oct 2026: 63Nov 2026: 41508 papers in 12 months
Cancer Prevention Research

Low predicted muscle mass showed no strong link to cancer risk

Men with low predicted muscle mass had a hazard ratio of 1.04 for overall cancer versus other men—a small difference in relative risk.Men with low predicted muscle mass had a hazard ratio of 1.04 for overall cancer versus other men—a small difference in relative risk.

Cohort · 4,441,403 peopleCancer
medRxiv

Water chemicals linked to death risk in men with prostate cancer

One chemical had a 1.07 adjusted hazard ratio—a relative death-rate measure—for death from any cause in the second-lowest versus lowest fifth of estimated exposure.One chemical had a 1.07 adjusted hazard ratio—a relative death-rate measure—for death from any cause in the second-lowest versus lowest fifth of estimated exposure.

Preprint: cohort · 51,289 peopleProstate cancer
Cancer

Prostate screening trade-offs worsen with age in models

Models estimated 2.7–3.1 overdiagnoses per prostate cancer death prevented at 72 versus 4.5–5.1 at 76 in men without other illnesses.Models estimated 2.7–3.1 overdiagnoses per prostate cancer death prevented at 72 versus 4.5–5.1 at 76 in men without other illnesses.

Computational studyInterventions

See all 1,427 papers on prostate cancer